ENHERTU® Approved in the U.S. for Patients with HER2 Positive Metastatic Breast Cancer Treated with a Prior Anti-HER2-Based RegimenBusiness Wire • 05/05/22
AstraZeneca revenue surges $11.39 billion, but sees COVID vaccine sales declineMarket Watch • 04/29/22
ENHERTU® Granted Breakthrough Therapy Designation in U.S. for Patients with HER2 Low Metastatic Breast CancerBusiness Wire • 04/27/22
Tremelimumab accepted under Priority Review in the US for patients with unresectable liver cancer in combination with ImfinziBusiness Wire • 04/25/22
AstraZeneca's Tremelimumab/Imfinzi Combo Regime Goes Under Priority FDA Review For Liver CancerBenzinga • 04/25/22
AstraZeneca says tremelimumab accepted for US Priority Review for Imfinzi combo for liver cancer treatmentProactive Investors • 04/25/22
AGM votes at HSBC, Glencore and AstraZeneca on climate change, pay may face strong oppositionProactive Investors • 04/21/22
AstraZeneca a 'buy' for Deutsche Bank after lung cancer drug granted priority reviewProactive Investors • 04/20/22
AstraZeneca cancer drug receives priority FDA review as data points to its potential in lung cancerProactive Investors • 04/19/22
ENHERTU® Granted Priority Review in the U.S. for Patients with Previously Treated HER2 Mutant Metastatic Non-Small Cell Lung CancerBusiness Wire • 04/19/22
AmoyDx Enters into Master Collaboration Agreement with AstraZeneca for Multiple Companion Diagnostics Programs in China, EU and JapanGlobeNewsWire • 04/18/22